02/11
Headlines

Discovery Laboratories

Biotech Losers: Discovery Laboratories (NASDAQ:DSCO), CEL-SCI Corporation (NYSEMKT:CVM), NewLink Genetics (NASDAQ:NLNK), La Jolla Pharmaceutical (NASDAQ:LJPC)

Mark Doerr02 mins

Discovery Laboratories, Inc. (NASDAQ:DSCO) has been upgraded by TheStreet Ratings from sell to hold. Discovery Laboratories, Inc. (NASDAQ:DSCO) stock performance was -6.01% in last session and finished the day at $2.19. Traded volume was 1,245,476 million shares in the last session and the average volume of the stock remained 589.46 million shares. The beta of…

Read More

Biotech Unusual Volume: OXiGENE Inc (NASDAQ:OXGN), TESARO Inc (NASDAQ:TSRO), Discovery Laboratories (NASDAQ:DSCO), Albany Molecular Research (NASDAQ:AMRI)

Jason Knox02 mins

OXiGENE Inc (NASDAQ:OXGN) on Mar. 11 announced positive results from a randomized Phase 2 clinical trial evaluating Avastin(R) (bevacizumab) with or without ZYBRESTAT(R) (fosbretabulin; CA4P) to treat patients with recurrent ovarian cancer. The study, known as Gynecologic Oncology Group protocol 186I, met its primary endpoint of a statistically significant increase in progression-free survival (p-value less…

Read More